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Abstract.22
Background: Frontotemporal lobar degeneration with TDP-43 immunoreactive inclusions (FTLD-TDP) may appear as
sporadic (sFTLD-TDP) or linked to mutations in various genes including expansions of the non-coding region of C9ORF72
(c9FTLD).
23
24
25
Objective: Analysis of differential mRNA and protein expression in the frontal cortex in c9FLTD and evaluation with previous
observations in frontal cortex in sFTLD-TDP and amyotrophic lateral sclerosis with TDP-43 inclusions.
26
27
Methods: Microarray hybridization and mass spectrometry-based quantitative proteomics followed by RT-qPCR, gel elec-
trophoresis, and western blotting in frontal cortex area 8 in 19 c9FTLD cases and 14 age- and gender-matched controls.
Results: Microarray hybridization distinguish altered gene transcription related to DNA recombination, RNA splicing reg-
ulation, RNA polymerase transcription, myelin synthesis, calcium regulation, and ubiquitin-proteasome system in c9FTLD;
proteomics performed in the same tissue samples pinpoints abnormal protein expression involving apoptosis, inflammation,
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metabolism of amino acids, metabolism of carbohydrates, metabolism of membrane lipid derivatives, microtubule dynamics,
morphology of mitochondria, neuritogenesis, neurotransmission, phagocytosis, receptor-mediated endocytosis, synthesis of
reactive oxygen species, and calcium signaling in c9FTLD.
33
34
35
Conclusion: Transcriptomics and proteomics, as well as bioinformatics processing of derived data, reveal similarly altered
pathways in the frontal cortex in c9FTLD, but different RNAs and proteins are identified by these methods. Combined
non-targeted ‘-omics’ is a valuable approach to deciphering altered molecular pathways in FTLD provided that observations
are approached with caution when assessing human postmortem brain samples.
36
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INTRODUCTION33
Frontotemporal lobar degeneration with TDP-4334
inclusions (FTLD-TDP) is manifested by behavioral-35
dysexecutive disorder, primary progressive aphasia,36
and/or motor disorders including motor neuron dis-37
ease due to frontal and temporal atrophy, as well38
as variable involvement of the basal ganglia, sub-39
stantia nigra, and spinal cord. Neuron loss in the40
cerebral cortex, microvacuolation in the upper corti-41
cal layers, astrogliosis, and TDP-43-immunoreactive42
inclusions in the nucleus and/or cytoplasm of neu-43
rons and oligodendocytes and in neuropil threads,44
are the main microscopical alterations [1–4]. Some45
cases are sporadic (sFTLD-TDP) whereas oth-46
ers are genetic, often familial (fFTLD-TDP) and47
linked to mutations in various genes including48
GRN (progranulin), C9ORF72 (chromosome 9 open49
reading frame 72), TARDP (TAR DNA-binding pro-50
tein), VCP (valosin-containing protein), CHMBP251
(charged multivesicular body protein 2), and UBQLN52
(ubiquilin 2), among others [4, 5–8]. The presence53
of TDP-43 inclusions in amyotrophic lateral sclero-54
sis (ALS), together with the fact that mutations in55
the same genes, excepting GRN, may be causative of56
ALS, suggests that ALS and FTLD-TDP are within57
the same disease spectrum [9–13].58
C9ORF72 expansions produce haploinsufficiency59
of C9orf72 protein, RNA foci sequestering of vari-60
ous RNA-binding proteins, dipeptide repeat protein61
inclusions probably sequestering additional proteins,62
abnormal protein binding, TDP-43 aggregation and63
loss of function, nucleocytoplasmic transport defects,64
RNA mis-splicing, DNA damage, abnormal stress65
granule dynamics, and altered autophagy, among oth-66
ers [8, 14–41].67
Complementary information has been gained from68
the application of transcriptomics and proteomics in69
FTLD-TDP and ALS [42–45] but studies including70
FTLD linked to C9ORF72 expansion (c9FTLD) are71
scarce [46]. The present study was designed to gain72
understanding about c9FTLD pathogenesis by using 73
microarray hybridization and mass spectrometry- 74
based quantitative proteomics in frontal cortex area 75
8 postmortem samples. Data were then processed 76
using bioinformatics methods to identify altered 77
molecular pathways and their interactions. Finally, 78
data obtained in c9FTLD were compared with those 79
previously obtained in the same cortical region in 80
sFTLD-TDP and sALS. 81
MATERIAL AND METHODS 82
Human cases 83
Postmortem fresh-frozen frontal cortex (FC) 84
(Brodmann area 8) samples were obtained from 85
the Institute of Neuropathology HUB-ICO-IDIBELL 86
Biobank and the Hospital Clinic-IDIBAPS Biobank 87
following the guidelines of Spanish legislation on 88
this matter and approval of the local ethics com- 89
mittees. The postmortem interval between death 90
and tissue processing was between 2 and 18 h. 91
One hemisphere was immediately cut in coronal 92
sections, 1 cm thick, and selected areas of the 93
encephalon were rapidly dissected, frozen on metal 94
plates over dry ice, placed in individual air-tight 95
plastic bags, and stored at –80◦C until use for bio- 96
chemical studies. The other hemisphere was fixed 97
by immersion in 4% buffered formalin for 3 weeks 98
for morphological studies. FTLD-TDP cases were 99
diagnosed following well-established criteria [1]. 100
All cases bore C9ORF72 repeat expansion (more 101
than 30 intronic hexanucleotide repeats). TDP-43- 102
immunoreactive inclusions were found in the frontal 103
cortex in every case; these were neuronal cytoplas- 104
mic inclusions mainly in layer II but also in the 105
deeper layers in some cases, together with dystrophic 106
neurites corresponding to types A and B [47], and 107
sequential pattern II-III [48]. Patients with associ- 108
ated pathologies, including middle or late stages of 109
Alzheimer’s and Parkinson’s diseases, and those with 110
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vascular diseases, neoplastic disorders affecting the111
nervous system, metabolic syndrome, hypoxia, and112
prolonged axonal states such as those occurring in113
intensive care units, were excluded. The whole series114
included 19 familial cases of fFTLD associated with115
C9ORF72 mutation, henceforth named c9FTLD for116
practical purposes (mean age 70 years; 10 men and117
9 women), and 14 cases (mean age 67 years; 8 men118
and 6 women) not suffering from neurologic or psy-119
chiatric diseases, and without abnormalities in the120
neuropathologic examination, which were assessed121
in parallel as age-matched controls (Table 1). Details122
of the clinical symptoms were very brief in the accom-123
panying data provided with the brain samples used124
for study. Apathy, loss of empathy, disinhibition,125
executive dysfunction, memory loss, hallucinations,126
and delusions were common, often accompanied by127
motor neuron disease; parkinsonism and progressive128
aphasia were reported in some cases.129
RNA purification130
RNA from frozen frontal cortex area 8 was131
extracted following the instructions of the supplier132
(RNeasy Mini Kit, Qiagen® GmbH, Hilden, Ger-133
many). RNA integrity and 28S/18S ratios were134
determined with the Agilent Bioanalyzer (Agilent135
Technologies Inc, Santa Clara, CA, USA) to assess136
RNA quality combined with DNase digestion to avoid137
extraction and later amplification of genomic DNA,138
and the RNA concentration was evaluated using139
a NanoDrop™ Spectrophotometer (Thermo Fisher140
Scientific, Waltham, MA, USA). RIN values are141
shown in Table 1. Special care was taken to assess pre-142
mortem and postmortem factors which may interfere143
with RNA processing [49].144
Microarray hybridization145
Samples were analyzed by microarray hybridiza-146
tion with Human Clariom™ D Assay kit and147
GeneChip WT Plus Reagent Kit, and microarray148
7000G platform from Affymetrix® (Affymetrix,149
Santa Clara, CA, USA) with a capacity to detect more150
than 540,000 transcripts. Preprocessing of raw data151
and statistical analyses were performed using biocon-152
ductor packages in an R programming environment153
for genes [50] which enabled data preprocessing for154
differential gene expression analysis and enrichment155
analysis. Gene selection was based upon their val-156
ues using a test for differential expression between157
two classes (Student’s t-test). Genes differentially158
Table 1
Summary of the thirty-three cases analyzed, including frontal cor-
tex area 8 of 14 controls and 19 fFTLD cases. c9FTLD, familial
FTLD linked to C9orf72 expansion; F, female; M, male; PMD,
postmortem delay (hours, minutes); RIN, RNA integrity number
Case Sex Age Diagnosis PMD RIN
1 M 66 Control 18 h 00 min 6.4
2 M 61 Control 03 h 40 min 7.0
3 M 62 Control 05 h 45 min 5.0
4 M 74 Control 06 h 40 min 7.2
5 M 65 Control 05 h 15 min 6.8
6 F 64 Control 02 h 15 min 5.0
7 M 63 Control 08 h 05 min 7.1
8 F 79 Control 03 h 35 min 6.8
9 F 67 Control 05 h 20 min 6.2
10 M 70 Control 03 h 45 min 7.2
11 M 52 Control 04 h 40 min 7.2
12 F 52 Control 05 h 45 min 5.1
13 F 82 Control 07 h 35 min 5.2
14 F 74 Control 02 h 45 min 5.7
15 M 69 c9FTLD 11 h 30 min 6.5
16 F 69 c9FTLD 13 h 15 min 5.4
17 M 68 c9FTLD 02 h 30 min 6.8
18 M 61 c9FTLD 07 h 45 min 6.9
19 M 66 c9FTLD 15 h 15 min 7.9
20 F 55 c9FTLD 03 h 15 min 8.7
21 M 69 c9FTLD 05 h 00 min 6.1
22 F 75 c9FTLD 17 h 30 min 7.5
23 F 92 c9FTLD 09 h 15 min 7.1
24 F 58 c9FTLD 11 h 00 min 8.4
25 F 66 c9FTLD 11 h 30 min 8,1
26 M 73 c9FTLD 15 h 30 min 6.2
27 F 69 c9FTLD 12 h 30 min 5.9
28 F 57 c9FTLD 03 h 40 min 7.2
29 M 80 c9FTLD 12 h 00 min 8.0
30 F 57 c9FTLD 08 h 00 min 6.9
31 M 88 c9FTLD 05 h 00 min 7.3
32 M 69 c9FTLD 05 h 45 min 7.1
33 M 80 c9FTLD 08 h 30 min 6.5
expressed showed an absolute fold change >2.0 in 159
combination with a p-value ≤ 0.05. 160
RT and q-PCR 161
Complementary DNA (cDNA) preparation used 162
the High-Capacity cDNA Reverse Transcription 163
kit (Applied Biosystems, Foster City, CA, USA) 164
following the protocol provided by the supplier. 165
Parallel reactions for each RNA sample were run 166
in the absence of MultiScribe Reverse Transcriptase 167
to assess the lack of contamination of genomic 168
DNA. TaqMan RT-qPCR assays were performed 169
in duplicate for each gene on cDNA samples in 170
384-well optical plates using an ABI Prism 7900 171
Sequence Detection System (Applied Biosystems). 172
For each 10L TaqMan reaction, 4.5L cDNA was 173
mixed with 0.5L 20× TaqMan Gene Expression 174
Assays and 5L of 2× TaqMan Universal PCR 175
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Table 2
Genes, gene symbols, and TaqMan probes used for the study of gene expression including probe for normalization (GUS-)
Gene Full name Reference
C9ORF72 Chromosome 9 Open Reading Frame 72 Hs00376619 m1
CNP 2′,3′-Cyclic Nucleotide 3′ Phosphodiesterase Hs00263981 m1
DDX3Y DEAD-Box Helicase 3 Y-Linked Hs00190539 m1
EIF1AY Eukaryotic Translation Initiation Factor 1A Y-Linked Hs01040047 m1
GPN2 GPN-Loop GTPase 2 Hs00216252 m1
GUS- -glucuronidase Hs00939627 m1
MAG Myelin Associated Glycoprotein Hs01114387 m1
MAL Mal, T-Cell Differentiation Protein Hs00360838 m1
MBP Myelin Basic Protein Hs00921945 m1
MOBP Myelin-Associated Oligodendrocyte Basic Protein Hs01094434 m1
MOG Myelin Oligodendrocyte Glycoprotein Hs01555268 m1
MYRF Myelin Regulatory Factor Hs00973739 m1
NG2 Neural/glial antigen 2 Hs00426981 m1
OLIG1 Oligodendrocyte Transcription Factor 1 Hs00744293 s1
OLIG2 Oligodendrocyte Lineage Transcription Factor 2 Hs00377820 m1
PLP1 Proteolipid Protein 1 Hs00166914 m1
SCARNA2 Small Cajal Body-Specific RNA 2 Hs04232660 s1
SOX-10 SRY-Box 10 Hs00366918 m1
TARDBP TAR DNA Binding Protein Hs00606522 m1
UBR5 Ubiquitin Protein Ligase E3 Component N-Recognin 5 Hs00210750 m1
Master Mix (Applied Biosystems) [51]. Table 2176
shows identification numbers and names of selected177
TaqMan probes. Values for glucuronidase- (GUS-178
) were used as internal controls for normalization.179
The selection of this housekeeping gene was based180
on previous data showing its low vulnerability in the181
brain in several human neurodegenerative diseases182
[52]. The parameters of the reactions were 50◦C183
for 2 min, 95◦C for 10 min, and 40 cycles of 95◦C184
for 15 s, and 60◦C for 1 min. Finally, all TaqMan185
PCR data were captured with Sequence Detection186
Software (SDS version 2.2.2, Applied Biosystems).187
The double-delta cycle threshold (CT) method188
was used to analyze the data. Results were analyzed189
using Student’s t-test [50].190
Proteomic analysis191
Sample preparation for proteomic analysis192
Frozen samples of frontal cortex from eight193
c9FTLD and eight controls of the same case194
series were homogenized in lysis buffer contain-195
ing 7 M urea, 2 M thiourea, and 50 mM DTT. The196
homogenates were spun down at 100,000 ×g for 1 h197
at 15◦C. Protein concentration was measured in the198
supernatants with the Bradford assay kit (Biorad,199
Hercules, CA, USA).200
Label free LC-MS/MS201
The protein extract for each sample was diluted in202
Laemmli sample buffer and loaded into a 0.75 mm203
thick polyacrylamide gel with a 4% stacking gel cast204
over a 12.5% resolving gel. The run was stopped as 205
soon as the front entered 3 mm into the resolving 206
gel so that the whole proteome became concentrated 207
in the stacking/resolving gel interface. Bands were 208
stained with Coomassie Brilliant Blue and excised 209
from the gel. Protein enzymatic cleavage (20g) was 210
carried out with trypsin (1:20, w/w, Promega, Madi- 211
son, WI, USA) at 37◦C for 16 h. Purification and 212
concentration of peptides was performed using C18 213
Zip Tip Solid Phase Extraction (Millipore, Burling- 214
ton, MA, USA). Peptide mixtures were separated 215
by reverse phase chromatography using an Eksigent 216
nanoLC ultra 2D pump fitted with a 75m ID column 217
(Eksigent 0.075 × 250). Samples were first loaded 218
for desalting and concentration into a 0.5 cm length 219
100m ID pre-column packed with the same chem- 220
istry as the separating column. Mobile phases were 221
100% water, 0.1% formic acid (FA) (buffer A), and 222
100% acetonitrile 0.1% FA (buffer B). Column gra- 223
dient was developed in a two-step gradient from 5% 224
B to 25% B for 210 min and 25%B to 40% B for 225
30 min. The column was equilibrated in 95% B for 226
9 min and 5% B for 14 min. During the entire process, 227
pre-column was in line with column, and the flow 228
maintained all along the gradient at 300 nl/min. Elut- 229
ing peptides from the column were analyzed using an 230
AB Sciex 5600 Triple-TOF system (Sciex). Informa- 231
tion data were acquired upon a survey scan performed 232
in a mass range from 350 m/z up to 1,250 m/z in a 233
scan time of 250 ms. The top 35 peaks were selected 234
for fragmentation. Minimum accumulation time for 235
MS/MS was set at 100 ms, yielding a total cycle time 236
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of 3.8 s. Product ions were scanned in a mass range237
from 230 m/z up to 1,500 m/z and excluded for further238
fragmentation for 15 s.239
Peptide identification and quantification240
MS/MS data acquisition was performed using241
Analyst 1.7.1 (Sciex) and spectra files were processed242
through Protein Pilot Software (v.5.0-Sciex) using243
Paragon™ algorithm (v.4.0.0.0) for database search244
and Progroup™ for data grouping, and then searched245
against the concatenated target-decoy UniProt pro-246
teome reference Human database (Proteome ID:247
UP000005640, 70902 proteins, December 2015).248
False discovery rate was identified using a non-249
lineal fitting method [53], and displayed results250
were those reporting a 1% global false discov-251
ery rate or better. The peptide quantification was252
performed using the Progenesis LC–MS software253
(version 2.0.5556.29015, Nonlinear Dynamics, New-254
castle, UK). Using the accurate mass measurements255
from full survey scans in the TOF detector and the256
observed retention times, runs were aligned to com-257
pensate for between-run variations in our nanoLC258
separation system. To this end, all runs were aligned259
to a reference run automatically chosen by the soft-260
ware, and a master list of features considering m/z261
values and retention times was generated. The quality262
of these alignments was manually supervised with the263
help of quality scores provided by the software. The264
peptide identifications were exported from Protein265
Pilot software and imported into Progenesis LC-MS266
software, where they were matched to the respec-267
tive features. Output data files were managed using268
Perseus Software for subsequent statistical analy-269
ses and representation [54]. Proteins identified by270
site (identification based only on a modification),271
reverse proteins (identified by decoy database), and272
potential contaminants were filtered out. Proteins273
quantified with at least two unique peptides, a p-274
value lower than 0.05 and an absolute fold change275
of <0.77 (downregulation) or >1.3 (upregulation) in276
linear scale, were considered to be significantly dif-277
ferentially expressed. MS raw data and search results278
files were deposited in the ProteomeXchange Consor-279
tium (http://proteomecentral.proteomexchange.org)280
via the PRIDE partner repository with the dataset281
identifiers PXD011713.282
Proteome bioinformatic analysis283
The specifically dysregulated regula-284
tory/metabolic networks identified in c9FTLD were285
analyzed with the use of QIAGEN’s Ingenuity®286
Pathway Analysis (IPA) (QIAGEN Redwood City, 287
CA, USA, http://www.qiagen.com/ingenuity). 288
This software comprises curated information from 289
databases of experimental and predictive origin, 290
enabling discovery of highly represented functions, 291
pathways, and interactome networks. 292
Gel electrophoresis and immunoblotting 293
Brain samples were homogenized in RIPA lysis 294
buffer (50 mM Tris/HCl buffer, pH 7.4 contain- 295
ing 2 mM EDTA, 0.2% Nonidet P-40, 1 mM 296
PMSF, protease, and phosphatase inhibitor cock- 297
tails, Roche Molecular Systems, Basel, Switzerland). 298
The homogenates were centrifuged for 15 min at 299
13,000 rpm. Protein concentrations were determined 300
with the BCA method (Thermo Fisher). Equal 301
amounts of protein (12g) for each sample were 302
loaded and separated by electrophoresis on sodium 303
dodecyl sulfate polyacrylamide gel electrophore- 304
sis (SDS-PAGE) (10%) gels and transferred onto 305
nitrocellulose membranes (Amersham, Freiburg, 306
Germany). Non-specific bindings were blocked by 307
incubation in 3% albumin in PBS containing 0.2% 308
Tween for 1 h at room temperature. After washing, 309
membranes were incubated overnight at 4◦C with the 310
antibody against C9orf72 (rabbit polyclonal used at 311
a dilution of 1:1,000; ab183982, Abcam, Cambridge, 312
UK), TDP43-T (rabbit polyclonal used at dilution of 313
1:250; ab154047, Abcam), SNAP25 (mouse mono- 314
clonal used at dilution of 1:1000, SMI81, BioLegend, 315
San Diego, CA, USA), CAMMKIIa (mouse mono- 316
clonal diluted 1:1,000; 13-7300, Zymed, MA, USA) 317
and CAMMKIV (mouse monoclonal diluted 1:1,000; 318
c28420, BD Biosciences, NJ, USA). Protein load- 319
ing was monitored using an antibody against -actin 320
(mouse monoclonal diluted 1:30,000; A5316, Sigma, 321
St. Louis, MO, USA). Membranes were then incu- 322
bated for 1h in the appropriate HRP-conjugated 323
secondary antibody (1:2,000 Agilent), and immuno- 324
complexes were revealed by chemiluminescence 325
reagent (ECL, Freiburg, Germany). Densitometric 326
quantification was carried out with ImageLab soft- 327
ware (Biorad). Bands were normalized to -actin. 328
Seven cases per group were analyzed. 329
Statistical analysis 330
The normality of distribution of fold change val- 331
ues was analyzed with the Kolmogorov-Smirnov 332
test. The non-parametric Mann-Whitney test was 333
performed to compare each group when values 334
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did not follow a normal distribution, whereas the335
unpaired t-test was used for normal variables. Statisti-336
cal analysis and graphic design were performed with337
GraphPad Prism version 5.01 (La Jolla, CA, USA).338
Outliers were detected using the GraphPad software339
QuickCalcs (p < 0.05). The data were expressed as340
mean ± SEM, and significance levels were set at341
∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001.342
RESULTS343
Microarray analysis344
Cofactors age, gender, RIN value, and postmortem345
delay were not relevant for the analysis. After fil-346
tering, 4,851 genes were included in the analysis.347
Gene expression in control and c9FTLD cases, with348
p-values equal to or lower than 0.05 and absolute349
fold change logarithm equal to or greater than 0.5,350
is represented in a heat-map (Fig. 1A). Forty-eight351
genes were differentially expressed in frontal cortex352
area 8 of c9FTLD when compared with controls (11 353
upregulated, 37 downregulated). Using GO database, 354
we identified clusters of deregulated genes related to 355
DNA recombination, RNA splicing regulation, RNA 356
polymerase transcription, and centriole (Fig. 1B). 357
Deregulated genes are listed in Table 3. In addition 358
to reported clusters, genes linked to myelin syn- 359
thesis, calcium regulation, and ubiquitin-protesome 360
system were also deregulated. Microarray details: 361
https://www.ebi.ac.uk/arrayexpress/; reference num- 362
ber fgsubs #218580. 363
Gene validation 364
Aberrant accumulation of hyper-phosphorylated 365
TDP43 and toxic aggregates of C9orf72 are com- 366
mon hallmarks in c9FTLD. mRNA levels of TARDBP 367
and C9ORF72 were evaluated with RT-qPCR. 368
C9ORF72 mRNA expression was significantly 369
decreased in c9FTLD when compared with con- 370
trols (p = 0.003), in line with the results of the array 371
Fig. 1. Microarray analysis. A) Hierarchical clustering heat-map of expression intensities of mRNA array transcripts in frontal cortex area
8 in c9FTLD compared with controls. B) GO database identifies clusters of deregulated genes in c9FTLD. Genes differentially expressed
show an absolute fold change >2.0 in combination with a p-value ≤ 0.05.
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Table 3
Deregulated genes in FC of c9FTLD cases
Gene ID Coding protein Deregulation FC p
NLGN4Y Neuroligin 4 Y-Linked Down –1.66 0.016
DDX3Y DEAD-Box Helicase 3 Y-Linked Down –1.42 0.040
EIF1AY Eukaryotic Translation Initiation Factor 1A Y-Linked Down –1,16 0.020
CHRM5 Cholinergic Receptor Muscarinic 5 Down –0.90 0.010
PWRN3 Prader-Willi Region Non-Protein Coding RNA 3 Down –0.73 0.002
MICU3 Mitochondrial Calcium Uptake Family Member 3 Down –0.73 0.002
MBP Myelin Basic Protein Down –0.68 0.044
PLPPR1 Phospholipid Phosphatase Related 1 Down –0.70 0.043
CD38 CD38 Molecule Down –0.64 0.005
LINC01476 Long Intergenic Non-Protein Coding RNA 1476 Down –0.60 0.001
C9orf72 Chromosome 9 Open Reading Frame 72 Down –0.60 0.006
UBR5 Ubiquitin Protein Ligase E3 Component N-Recognin 5 Down –0.60 0.000
KIAA0040 Uncharacterized Protein KIAA0040 Down –0,60 0.029
ALOX5AP Arachidonate 5-Lipoxygenase Activating Protein Down –0.59 0.032
TGFB3 Transforming Growth Factor Beta 3 Down –0.59 0.030
CD9 CD9 Molecule Down –0.58 0.048
CCDC102B Coiled-Coil Domain Containing 102B Down –0.57 0.011
LOC253573 Uncharacterized LOC253573 Down –0.57 0.005
EPDR1 Ependymin Related 1 Down –0.57 0.001
ZBBX Zinc Finger B-Box Domain Containing Down –0.57 0.040
CYP2C8 Cytochrome P450 Family 2 Subfamily C Member 8 Down –0.57 0.015
CLIC2 Chloride Intracellular Channel 2 Down –0.56 0.015
ST6GAL2 ST6 Beta-Galactoside Alpha-2,6-Sialyltransferase 2 Down –0.56 0.024
RASGEF1B RasGEF Domain Family Member 1B Down –0.54 0.030
MIR4740 Hsa-Mir-4740 Down –0.53 0.034
ANGPT2 Angiopoietin 2 Down –0.53 0.027
S100A11 S100 Calcium Binding Protein A11 Down –0.53 0.036
UCHL3 Ubiquitin C-Terminal Hydrolase L3 Down –0.53 0.027
TLCD1 Calfacilitin Down –0.52 0.024
ARMC2 Armadillo Repeat Containing 2 Down –0.52 0.014
CYP1B1-AS1 CYP1B1 Antisense RNA 1 (Non-Protein Coding) Down –0.52 0.024
LINC01140 Long Intergenic Non-Protein Coding RNA 1140 Down –0.52 0.004
GPN2 GPN-Loop GTPase 2 Down –0.52 0.015
AKIRIN2 Akirin 2 Down –0.52 0.007
SLC39A8 Solute Carrier Family 39 (Metal Ion Transporter), Member 8 Down –0.51 0.031
SCARNA2 Small Cajal Body-Specific RNA 2 Down –0.50 0.027
CDC14B Cell Division Cycle 14B Down –0.50 0.044
LOC100506990 Uncharacterized LOC100506990 Up 0.51 0.036
VPS13D Vacuolar Protein Sorting 13 Homolog D Up 0.51 0.016
LINC00499 Long Intergenic Non-Protein Coding RNA 499 Up 0.52 0.011
DDR2 Discoidin Domain Receptor Tyrosine Kinase 2 Up 0.54 0.017
RHNO1 RAD9-HUS1-RAD1 Interacting Nuclear Orphan 1 Up 0.55 0.018
IFIT3 Interferon Induced Protein With Tetratricopeptide Repeats 3 Up 0.55 0.034
IGF2BP3 Insulin-like Growth Factor 2 MRNA Binding Protein 3 Up 0.55 0.024
LOC100190986 Uncharacterized LOC100190986 Up 0.56 0.034
SNORA11 Small Nucleolar RNA, H/ACA Box 11 Up 0.57 0.048
TSIX TSIX Transcript, XIST Antisense RNA Up 0.67 0.021
XIST X Inactive Specific Transcript Up 2.22 0.043
(Fig. 2A). TARDBP mRNA levels were not signifi-372
cant altered in c9FTLD when compared with controls373
(p = 0.15).374
Significant increase in UBR5 (p = 0.03) and375
DD3XY (p = 0.026) mRNAs was confirmed by RT-376
qPCR. Expression levels of SCARNA2 (p = 0.83),377
EIF1AY (p = 0.36), and GPN2 (p = 0.76), although378
reduced in the array, were preserved when assessed379
with RT-qPCR (Fig. 2B).380
MBP mRNA expression was significantly 381
decreased in c9FTLD (p = 0.05) (Fig. 2C). To further 382
extend knowledge about genes linked to myelin 383
and oligodendrocytes, RT-qPCR revealed reduced 384
expression of MAG (p = 0.036), MAL (p = 0.02), 385
MOBP (p = 0.025), and MOG (p = 0.05) in c9FTLD 386
when compared with controls (Fig. 2C). How- 387
ever, the expression of OLIG1 (p = 0.17), OLIG2 388
(p = 0.40), SOX10 (p = 0.33), NG2 (p = 0.34), MYRF 389
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Fig. 2. mRNA expression of selected genes in c9FTLD. A) Expression levels of genes C9ORF72 and TARDBP. B) Relative expression
levels of genes linked to DNA/RNA regulation mechanisms. C) Expression levels of genes coding for myelin and oligodendrocyte proteins.
The significance level is set at ∗p < 0.05.
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(p = 0.23), CNP (p = 0.065), and PLP1 (p = 0.07)390
was not altered in c9FTLD (Fig. 2C). None of these391
genes, excepting MBP, was identified as deregulated392
in the arrays.393
Cortical proteostatic impairment in c9FTLD394
To probe additional molecular disturbances in395
frontal cortex (area 8) from c9FTLD cases with396
respect to neurologically intact controls, a label-free397
MS-based approach was used. Postmortem delay was398
not relevant for the study. Among 3,909 identified399
proteins, the differential frontal cortex site-specific400
proteomic signature was composed of 130 proteins401
(40 downregulated and 90 upregulated) in c9FTLD402
cases when compared with controls. A heat-map rep-403
resenting the fold-change of identified proteins with404
associated p-values from the pair-wise quantitative405
comparisons, and a Volcano plot showing the distri-406
bution of differentially expressed proteins in c9FTLD407
and controls, are depicted in Fig. 3. Deregulated pro-408
teins are listed in Table 4.409
Cortical deregulated pathways in c9FTLD410
To enhance the analytical outcome of pro-411
teomic experiments, differential proteome datasets412
were functionally analyzed across specific biolog-413
ical functions using IPA software. Bioinformatic414
analysis revealed clusters categorized under the 415
terms apoptosis, inflammation, metabolism of amino 416
acids, metabolism of carbohydrates, metabolism of 417
membrane lipid derivatives, microtubule dynam- 418
ics, morphology of mitochondria, neuritogenesis, 419
neurotransmission, phagocytosis, receptor-mediated 420
endocytosis, and synthesis of reactive oxygen species 421
as altered pathways in c9FTLD (Table 5). Addi- 422
tional integrative network unveiled disruptions in 423
calcium signalling (NECAB1, CAMMKK2 and 424
CNTN2), calmodulin function, and vesicle release 425
(CLSTN1) (Fig. 4 and Table 4). Moreover, the 426
protein interactome map showed deregulation of 427
cross-linkers between DNA/RNA regulation systems 428
and ubiquitin-proteasome systems, suggesting an 429
imbalance in cellular transcription processes and pro- 430
tein degradation mechanisms in c9FTLD (Fig. 4). 431
Monitoring the frontal cortical expression of 432
specific protein mediators in c9FTLD 433
In order to partially validate the results obtained 434
by LC-MS/MS, western-blotting was used as an 435
orthogonal technique. To complement our study, 436
total TDP43 protein levels were increased in 437
c9FTLD when compared with controls (p = 0.02). 438
C9orf72 long isoform was significantly reduced 439
(p = 0.04) whereas C9orf72 short isoform was signif- 440
icantly increased (p = 0.000) in c9FTLD (Fig. 5). In 441
Fig. 3. Differentially expressed proteins in frontal cortex area 8 in c9FTLD. A) Heat map representing the fold-change of identified proteins
with associated p-values from the pair-wise quantitative comparisons with controls. Significantly upregulated proteins in c9FTLD between
pair-wise comparisons are labelled in green, and significantly downregulated proteins are labelled in red. B) Volcano plot of differentially
expressed proteins.
Un
co
rre
cte
d A
uth
or
 P
ro
of
10 P. Andre´s-Benito et al. / Frontal Cortex in FTLD Linked to C9ORF72 Expansion
Table 4
Deregulated proteins in c9FTLD compared with controls
Gene Protein name Uniprot Deregulation FC p
RAP1GAP Rap1 GTPase-activating protein 1 X6R8W7 Down 0.77 0.01
CLIP2 CAP-Gly domain-containing linker protein 2 Q9UDT6 Down 0.77 0.02
SUGT1 Protein SGT1 homolog Q9Y2Z0 Down 0.76 0.00
AAK1 AP2-associated protein kinase 1 Q2M2I8 Down 0.76 0.01
DYNC1LI1 Cytoplasmic dynein 1 light intermediate chain 1 Q9Y6G9 Down 0.76 0.00
PRKCB Protein kinase C beta type P05771 Down 0.75 0.00
PRKCG Protein kinase C gamma type P05129 Down 0.75 0.04
CLTC Clathrin heavy chain 1 Q00610 Down 0.75 0.00
GAS7 Growth arrest-specific protein 7 O60861 Down 0.74 0.03
NPTX1 Neuronal pentraxin-1 Q15818 Down 0.74 0.03
ARHGEF2 Rho guanine nucleotide exchange factor 2 Q92974 Down 0.73 0.05
INA Internexin Neuronal Intermediate Filament Protein Alpha Q16352 Down 0.73 0.01
PUF60 Poly(U)-binding-splicing factor PUF60 Q9UHX1 Down 0.72 0.01
ATL1 Atlastin-1 Q8WXF7 Down 0.72 0.01
CNTN2 Contactin-2 A0A1W2PQ11 Down 0.72 0.02
GLTP Glycolipid transfer protein Q9NZD2 Down 0.71 0.05
PRRT2 Proline-rich transmembrane protein 2 Q7Z6L0 Down 0.70 0.00
AIDA Axin interactor, dorsalization-associated protein Q96BJ3 Down 0.69 0.00
CCDC6 Coiled-coil domain-containing protein 6 Q16204 Down 0.69 0.00
NCKIPSD NCK-interacting protein with SH3 domain Q9NZQ3 Down 0.69 0.05
PLD3 Phospholipase D3 Q8IV08 Down 0.69 0.01
RABL6 Rab-like protein 6 Q3YEC7 Down 0.68 0.01
INF2 Inverted formin-2 Q27J81 Down 0.68 0.03
AGL Glycogen debranching enzyme P35573 Down 0.67 0.03
APOE Apolipoprotein E P02649 Down 0.67 0.02
CAMKK2 Calcium/calmodulin-dependent protein kinase kinase 2 Q96RR4 Down 0.67 0.02
GPRIN1 G protein-regulated inducer of neurite outgrowth 1 Q7Z2K8 Down 0.65 0.02
OPTN Optineurin Q96CV9 Down 0.65 0.02
POR NADPH—cytochrome P450 reductase P16435 Down 0.64 0.00
ABLIM2 Actin-binding LIM protein 2 Q6H8Q1 Down 0.63 0.02
NECAB1 N-terminal EF-hand calcium-binding protein 1 Q8N987 Down 0.63 0.01
UGGT1 UDP-glucose:glycoprotein glucosyltransferase 1 Q9NYU2 Down 0.62 0.00
STRN4 Striatin-4 Q9NRL3 Down 0.61 0.04
DNAJC11 DnaJ homolog subfamily C member 11 Q9NVH1 Down 0.61 0.02
CLSTN1 Calsyntenin-1 O94985 Down 0.59 0.01
BAG6 Large proline-rich protein BAG6 P46379 Down 0.52 0.00
SLC2A3 Solute carrier family 2, facilitated glucose transporter memb r 3 P11169 Down 0.50 0.01
SEC24B Protein transport protein Sec24B O95487 Down 0.49 0.03
ANK3 Ankyrin-3 Q12955 Down 0.47 0.00
WDR47 WD repeat-containing protein 47 O94967 Down 0.45 0.00
CPNE1 Copine-1 Q99829 Up 1.30 0.03
GAPDH Glyceraldehyde-3-phosphate dehydrogenase P04406 Up 1.30 0.00
PHB Prohibitin P35232 Up 1.30 0.04
ADH5 Alcohol dehydrogenase class-3 P11766 Up 1.31 0.04
IDH1 Isocitrate dehydrogenase [NADP] cytoplasmic O75874 Up 1.31 0.01
MSN Moesin P26038 Up 1.31 0.05
CNDP2 Cytosolic non-specific dipeptidase Q96KP4 Up 1.32 0.01
ACAA2 3-ketoacyl-CoA thiolase, mitochondrial P42765 Up 1.33 0.00
PSMA6 Proteasome subunit alpha type-6 P60900 Up 1.33 0.03
HPX Hemopexin P02790 Up 1.34 0.02
PSMA4 Proteasome subunit alpha type-4 P25789 Up 1.34 0.03
SERPINB6 Serpin B6 P35237 Up 1.34 0.02
TARDBP TAR DNA-binding protein 43 Q13148 Up 1.34 0.02
BRSK1 Serine/threonine-protein kinase BRSK1 Q8TDC3 Up 1.36 0.03
ECH1 Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, mitochondrial Q13011 Up 1.37 0.03
PACSIN2 Protein kinase C and casein kinase substrate in neurons protein 2 Q9UNF0 Up 1.38 0.02
PPT1 Palmitoyl-protein thioesterase 1 P50897 Up 1.39 0.02
RAB7A Ras-related protein Rab-7a P51149 Up 1.40 0.02
REPS1 RalBP1-associated Eps domain-containing protein 1 Q96D71 Up 1.40 0.02
ALDH9A1 4-trimethylaminobutyraldehyde dehydrogenase P49189 Up 1.41 0.01
(Continued)
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Table 4
(continued)
Gene Protein name Uniprot Deregulation FC p
COPS2 COP9 signalosome complex subunit 2 P61201 Up 1.41 0.01
ECI2 Enoyl-CoA delta isomerase 2, mitochondrial O75521 Up 1.41 0.01
EEF1A1 Elongation factor 1-alpha 1 P68104 Up 1.41 0.01
FHL1 Four and a half LIM domains protein 1 (Fragment) Q5JXI8 Up 1.42 0.01
MPI Mannose-6-phosphate isomerase P34949 Up 1.43 0.01
CTSD Cathepsin D P07339 Up 1.45 0.01
CUTA Protein CutA O60888 Up 1.45 0.05
LHPP Phospholysine phosphohistidine inorganic pyrophosphate phosphatase Q9H008 Up 1.45 0.00
CSRP1 Cysteine and glycine-rich protein 1 P21291 Up 1.46 0.04
NUDT21 Cleavage and polyadenylation specificity factor subunit 5 O43809 Up 1.46 0.03
CLIC4 Chloride intracellular channel protein 4 Q9Y696 Up 1.47 0.04
LMNA Prelamin-A/C P02545 Up 1.49 0.03
SELENBP1 Selenium-binding protein 1 Q13228 Up 1.49 0.00
MTHFD1 C-1-tetrahydrofolate synthase, cytoplasmic P11586 Up 1.50 0.03
PNPO Pyridoxine-5′-phosphate oxidase Q9NVS9 Up 1.50 0.04
SKP1 S-phase kinase-associated protein 1 P63208 Up 1.50 0.05
DNPEP Aspartyl aminopeptidase Q9ULA0 Up 1.51 0.01
FBXO2 F-box only protein 2 Q9UK22 Up 1.51 0.01
HDHD2 Haloacid dehalogenase-like hydrolase domain-containing protein 2 Q9H0R4 Up 1.51 0.04
PEBP1 Phosphatidylethanolamine-binding protein 1 P30086 Up 1.51 0.04
SMS Spermine synthase P52788 Up 1.51 0.03
SRI Sorcin P30626 Up 1.51 0.00
PSAT1 Phosphoserine aminotransferase Q9Y617 Up 1.52 0.02
ANXA5 Annexin A5 P08758 Up 1.54 0.03
PHGDH D-3-phosphoglycerate dehydrogenase O43175 Up 1.54 0.01
GSTM5 Glutathione S-transferase Mu 5 P46439 Up 1.55 0.04
PLCD1 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase delta-1 P51178 Up 1.57 0.01
HSPB1 Heat shock protein beta-1 P04792 Up 1.60 0.03
NAXD ATP-dependent (S)-NAD(P)H-hydrate dehydratase Q8IW45 Up 1.60 0.02
PRDX2 Peroxiredoxin-2 P32119 Up 1.60 0.01
TPPP3 Tubulin polymerization-promoting protein family member 3 Q9BW30 Up 1.61 0.03
SOD2 Superoxide dismutase [Mn], mitochondrial P04179 Up 1.62 0.04
COPS8 COP9 signalosome complex subunit 8 Q99627 Up 1.63 0.00
CUL3 Cullin-3 A0A087WTG3 Up 1.63 0.00
CYCS Cytochrome c P99999 Up 1.63 0.02
PKM Pyruvate kinase PKM P14618 Up 1.71 0.00
TMLHE Trimethyllysine dioxygenase, mitochondrial Q9NVH6 Up 1.72 0.04
PSMA5 Proteasome subunit alpha type-5 P28066 Up 1.74 0.03
ARL3 ADP-ribosylation factor-like protein 3 P36405 Up 1.75 0.00
GSTP1 Glutathione S-transferase P P09211 Up 1.75 0.02
HBA1 Hemoglobin subunit alpha P69905 Up 1.75 0.01
CD81 CD81 antigen P60033 Up 1.77 0.00
PRDX1 Peroxiredoxin-1 Q06830 Up 1.77 0.01
NIT2 Omega-amidase NIT2 Q9NQR4 Up 1.79 0.03
AK1 Adenylate kinase isoenzyme 1 P00568 Up 1.81 0.01
GSTM2 Glutathione S-transferase E9PHN6 Up 1.81 0.05
AK3 GTP:AMP phosphotransferase AK3, mitochondrial Q9UIJ7 Up 1.82 0.01
FMOD Fibromodulin Q06828 Up 1.85 0.03
BLVRB Flavin reductase (NADPH) P30043 Up 1.91 0.00
NAE1 NEDD8-activating enzyme E1 regulatory subunit Q13564 Up 1.92 0.00
PRDX6 Peroxiredoxin-6 P30041 Up 1.93 0.01
HBB Hemoglobin subunit beta P68871 Up 1.94 0.01
NDUFB10 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 10 O96000 Up 1.94 0.01
DNAH8 Dynein heavy chain 8, axonemal Q96JB1 Up 1.98 0.02
IGKC Immunoglobulin kappa constant P01834 Up 1.99 0.01
ANXA2 Annexin A2 P07355 Up 2.09 0.03
ANXA1 Annexin A1 P04083 Up 2.10 0.04
LGALS1 Galectin-1 P09382 Up 2.12 0.01
EIF3I Eukaryotic translation initiation factor 3 subunit I Q13347 Up 2.13 0.05
SPTBN1 Spectrin beta chain, non-erythrocytic 1 Q01082 Up 2.22 0.04
(Continued)
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Table 4
(continued)
Gene Protein name Uniprot Deregulation FC p
PGLS 6-phosphogluconolactonase O95336 Up 2.26 0.03
COTL1 Coactosin-like protein Q14019 Up 2.35 0.03
MYL6 Myosin light polypeptide 6 P60660 Up 2.39 0.01
SNPH Syntaphilin O15079 Up 2.48 0.01
SPR Sepiapterin reductase P35270 Up 2.51 0.01
HBD Hemoglobin subunit delta P02042 Up 2.52 0.01
PGAM2 Phosphoglycerate mutase 2 P15259 Up 2.52 0.02
IAH1 Isoamyl acetate-hydrolyzing esterase 1 homolog Q2TAA2 Up 2.80 0.01
IGHG2 Immunoglobulin heavy constant gamma 2 P01859 Up 2.88 0.01
H2AFX Histone H2AX P16104 Up 4.17 0.04
Table 5
Main biofunctions of abnormally expressed proteins in frontal cortex area 8 in c9FTLD
Functional terms p Proteins
Apoptosis 0.000 PEBP1, PHGDH, PPT1, LGALS1, BAG6, PHB, SRI, PKM, CYCS, PRDX1, EIF3I,
H2AFX, LMNA, SPTBN1, PRDX6, POR, GSTM5, PRKCB, CLIC4, ADH5, NAE1,
PRDX2, GSTP1, CTSD, OPTN, CUL3, TARDBP, GAS7, PLCD1, EEF1A1, PUF60,
SLC2A3, CLTC, NPTX1, MSN, ANXA5, ANXA2, CCDC6, ANXA1, HSPB1,
SOD2, RABL6, GAPDH, APOE, SELENBP1, FMOD, PRKCG
Inflammation 0.000 PHGDH, PPT1, LGALS1, PHB, PKM, PRDX1, POR, PRDX6, CPNE1,
PRKCB, PRDX2, GSTP1, CTSD, OPTN, IGKC, EEF1A1, MSN, ANXA5, HBB,
ANXA1, SOD2, APOE, GAPDH, HPX, SELENBP1, COTL1, CD81
Metabolism of amino acids 0.000 PHGDH, MTHFD1, CNDP2, NIT2, PKM, IDH1, SMS
Metabolism of carbohydrate 0.000 AGL, PLCD1, EEF1A1, CLTC, PKM, ANXA1, PRDX6, MPI, PRKCB, CAMKK2,
GAPDH, PRDX2, APOE, IDH1, OPTN
Metabolism of membrane lipid derivative 0.004 PRDX6, POR, PLCD1, EEF1A1, PPT1, PRKCB, PRDX2, APOE, ANXA1
Microtubule dynamics 0.000 PHGDH, CSRP1, ATL1, CLSTN1, PKM, SPTBN1, PRKCB, CAMKK2,
ARL3, OPTN, CD81, GAS7, BRSK1, EEF1A1, PACSIN2, MSN, RAP1GAP,
NCKIPSD, CNTN2, ANK3, HSPB1, ARHGEF2, APOE, GAPDH, GPRIN1
Morphology of mitochondria 0.003 SOD2, SNPH, GAPDH, INF2, AK1
Neuritogenesis 0.000 BRSK1, CSRP1, LGALS1, NPTX1, RAP1GAP, SNPH, CNTN2, ANK3, SPTBN1,
APOE, CAMKK2, GPRIN1, GAS7, TARDBP
Neurotransmission 0.005 NPTX1, CLSTN1, PRKCB, FBXO2, SRI, SNPH, APOE, PRKCG, ANK3
Phagocytosis 0.001 RAB7A, CLTC, ANXA5, MSN, CLIC4, PRKCB, RAP1GAP, PRKCG, ANXA1
Receptor-mediated endocytosis 0.001 PACSIN2, PPT1, CLTC, REPS1, NAE1, APOE
Synthesis of reactive oxygen species 0.000 PHB, ANXA2, HBB, PRDX1, ANXA1, HSPB1, PRDX6, SOD2, PRKCB, PRDX2,
APOE, IDH1, GSTP1
addition, one synaptic protein, SNAP25, and two pro-442
teins linked with the calcium/calmodulin-dependent443
(CaM) kinase cascade were selected for valida-444
tion. SNAP25 was significantly decreased (p = 0.02),445
and CaMKII and CaMKIV protein levels were446
significantly reduced, in c9FTLD when compared447
with controls (p = 0.05 and p = 0.03, respectively)448
(Fig. 5).449
DISCUSSION450
This study analyzes differential mRNA and protein451
expression in frontal cortex area 8 in 19 fFTLD cases452
linked to C9ORF72 expansion (c9FTLD) and 14453
age- and gender-matched controls using microarray454
hybridization and 7000G platform technology from455
Affymetrix® and quantitative proteomics using LC-456
MS/MS, respectively. mRNA expression for selected457
genes was validated with RT-qPCR, and protein levels 458
with gel electrophoresis and western blotting. 459
Regarding TDP-43 and C9orf72, major pathologic 460
components in c9FTLD, TARDBP mRNA expres- 461
sion was preserved but total TDP-43 protein showed 462
increased levels in c9FTLD when compared with 463
controls. This is in accordance with the abnormal 464
deposition of this protein in intracellular inclusions 465
and threads characteristic of this disease. In con- 466
trast, C9ORF72 mRNA expression was significantly 467
decreased in c9FTLD. However, the C9orf72 long 468
isoform was significantly reduced and the C9orf72 469
short isoform significantly increased in c9FTLD. 470
Reduced C9ORF72 protein levels were found in pre- 471
vious reports [55–58]. The functional implications 472
of the reduced levels of the long C9orf72 isoform 473
are not known, but quantitative mass spectrometry- 474
based proteomics used to identify interacting proteins 475
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Fig. 4. High-scoring protein interactome map of differentially expressed proteins in the frontal cortex in c9FTLD. Visual representation
of the relationships between differentially expressed proteins and functional interactors. Downregulated proteins are highlighted in red and
upregulated proteins in green. Continuous and discontinuous lines represent direct and indirect interactions, respectively.
in motor neurons has shown that the long iso-476
form complex stabilizes SMCR8, a protein which477
acts as an autophagic regulator [59, 60]. Therefore,478
reduced levels of the long isoform may interfere479
with normal autophagy and lysosomal processing480
[60]. C9orf72 also binds to several proteins including481
members of the Rab family, endoplasmic reticulum482
and synapses; nuclear and cytoplasmic transport,483
endoplasmic reticulum stress, and altered synaptic484
function have all been reported in association with485
pathogenic C9ORF72 expansions [21, 22, 26, 28, 35, 486
39, 61]. 487
The present study reveals altered gene tran- 488
scription related to DNA recombination, RNA 489
splicing regulation, RNA polymerase transcrip- 490
tion, myelin synthesis, calcium regulation, and 491
ubiquitin-proteasome system in c9FTLD. Proteomics 492
performed in the same tissue samples identifies 493
altered protein expression linked to apoptosis, inflam- 494
mation, metabolism of amino acids, metabolism 495
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Fig. 5. Gel electrophoresis and western blotting to C9orf72 isoforms, and total TDP-43, CAMKIIa, and CAMKIV in frontal cortex area 8
in c9FTLD and controls. The protein expression of C9orf72 long isoform (54 kDa) is reduced in parallel with the increased protein level of
the C9orf72 short isoform (25 kDa). Total protein levels of TDP-43 are significantly increased in c9FTLD. CAMKII and CAMKIV protein
levels are significantly decreased. ∗p < 0.05 and ∗∗∗p < 0.001.
of carbohydrates, metabolism of membrane lipid496
derivatives, microtubule dynamics, morphology497
of mitochondria, neuritogenesis, neurotransmis-498
sion, phagocytosis, receptor-mediated endocytosis,499
synthesis of reactive oxygen species, and calcium 500
signaling in c9FTLD. 501
Genes and proteins do not match in the two lists 502
of deregulated mRNAs and proteins in c9FTLD 503
Un
co
rre
cte
d A
uth
or
 P
ro
of
P. Andre´s-Benito et al. / Frontal Cortex in FTLD Linked to C9ORF72 Expansion 15
Fig. 6. A) Venn’s diagram comparing transcriptomics and proteomics profile in c9FTLD based on the present observations. B–D) Overlap
of the transcriptomic profiles obtained in the frontal cortex area 8 in sALS, sFTLD-TDP, and c9FTLD based on the present observa-
tions and our previous studies cited in [45] and [51]. B) Venn’s diagram of downregulated genes in sALS, sFTLD, and c9FTLD. C)
Venn’s diagram of upregulated genes in sALS, sFTLD, and c9FTLD. D) Venn’s diagram of total deregulated genes in sALS, sFTLD, and
c9FTLD.
(Fig. 6A). However, a protein interactome map con-504
structed using the IPA software shows deregulation505
of cross-linkers between DNA/RNA regulation sys-506
tems and ubiquitin-proteasome systems, suggesting507
an imbalance in cellular transcription processes and508
protein degradation mechanisms, which makes sense509
in light of gene transcription observations of the main510
contributors to the pathogenesis of neurodegenerative511
diseases with abnormal protein aggregates, and it is512
particularly in line with the function of TDP-43 and 513
C9orf72. 514
Together, this combined transcriptomics- 515
proteomics analysis supports the list of separately 516
reported altered pathways linked to C9ORF72 517
mutations, including those involved in DNA 518
recombination and transcription, RNA splicing, 519
endoplasmic reticulum and mitochondria, synaptic 520
transmission, protein degradation, calcium home- 521
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ostasis, and inflammation [35, 37–39, 41, 61–66].522
Additional alterations involve altered metabolism523
of amino acids and carbohydrates, membrane lipid524
derivatives, and microtubule dynamics, and synthesis525
of reactive oxygen species. Links between oxidative526
and endoplasmic reticulum stress, TDP-43, and527
docosahexaenoic acid have been described in the528
spinal cord in ALS [67–69] but information is529
lacking about c9FTLD. Moreover, oxidative damage530
has been assessed and proven in FTLD-TDP [70],531
but no special focus on c9FTLD was provided in532
that study.533
An interesting deregulated cluster is composed534
of genes linked to several miRNAs, nuclear RNAs535
and long non-coding RNAs, including MIR4740, the536
small nucleolar RNA (SCARNA2), and long non-537
coding RNAs such as X-inactive specific transcript538
(XIST) and the long intergenic non-coding RNAs539
LINC1476, LINC1140, and LINC00499. miRNAS540
participate in a large number of variegated processes541
covering mRNA silencing and regulation of gene542
transcription [71, 72]. SCARNA2 localizes to Cajal543
bodies, the process of binding of its box C/D being544
modulated by coilin [73]. Long intergenic non-coding545
RNAs are mainly localized in the nucleus where546
they modulate chromatin and genome architecture, in547
addition to RNA stabilization and transcription regu-548
lation [74]. XIST is localized in the X-chromosome549
and participates in the inactivation of chromosome550
X [75]. The consequences of XIST deregulation in551
C9orf72 remains elusive.552
Our previous studies using a similar tran-553
scriptomics approach in frontal cortex area 8 in554
sFTLD-TDP have shown down-deregulation of genes555
linked to neurotransmission and synapses, neuronal556
architecture, cytoskeleton of axons and dendrites,557
vesicle trafficking, purines, mitochondria, and energy558
metabolism [45]. Additional protein and enzymatic559
studies have revealed altered mitochondrial function560
and oxidative phosphorylation [45]. Using the same561
methods, we observed upregulated gene clusters in562
frontal cortex area 8 in sALS involving neurotrans-563
mission, synaptic proteins, and vesicle trafficking,564
and downregulated genes clustering into oligoden-565
drocyte function and myelin-related proteins [51].566
Venn’s diagrams serve to illustrate downregulated567
and upregulated genes shared in these diseases:568
sALS, sFTLD-TDP, and c9FTLD (Fig. 6B–D).569
Curiously, some downregulated clusters related570
mainly to synapses and neurotransmission in frontal571
cortex in sFTLD-TDP were upregulated in frontal572
cortex in sALS without dementia [45, 51]. The573
present observations in c9FTLD reveal some com- 574
monalities with sFTLD-TDP in altered clusters but 575
not in particular genes. Downregulation of genes 576
linked to oligodendrocytes and myelin in frontal cor- 577
tex area 8 is shared in c9FTLD and sALS. 578
Recent studies have shown oligodendrocytes 579
as key players in neurodegenerative diseases 580
with abnormal protein aggregates [76]. Oligoden- 581
drogliopathy is common in sALS and FTLD-TDP. 582
Phosphorylated-TDP-43-immunoreactive oligoden- 583
droglial inclusions are found, in addition to spinal 584
cord motor neurons, in the motor, sensory and premo- 585
tor cortex, but not in the corpus callosum, cingulum 586
or lateral tracts of the spinal cord [77]. TDP-43 oligo- 587
dendroglial inclusions are common in the deep layers 588
of the cerebral cortex and white matter in FTLD-TDP 589
[78]. The functional effects of oligodendroglial TDP- 590
43 inclusions are not known, but present findings 591
indicate altered oligodendroglial gene expression 592
in the frontal cortex in c9FTLD. Particular fea- 593
tures are linked to C9orf72 hexanucleotide repeat 594
expansion [79, 80], and TDP-43-dependent or TDP- 595
43-independent oligodendroglial dysfunction might 596
be a characteristic trait linked to C9orf72 hexanu- 597
cleotide repeat expansion. 598
In contrast, although astrocytes play key 599
pathogenic roles in ALS [81], TDP-43- 600
immunoreactive inclusions are rare in sALS 601
and FTLD-TDP [82]. 602
Commonalities and discrepancies are also seen 603
when comparing the transcriptome of the frontal cor- 604
tex in sALS with no mutations and ALS linked to 605
C9orf72 mutations (c9ALS) [83]. The number and 606
type of deregulated genes in c9ALS was approx- 607
imately double that seen in sALS. For example, 608
alteration of the unfolded protein response and intra- 609
cellular protein transport were identified from genes 610
differentially upregulated in c9ALS but not in sALS, 611
whereas alterations in oxidative phosphorylation, 612
cytoskeleton, and synaptic transmission were pre- 613
dominant in frontal cortex in sALS [83]. These data 614
in frontal cortex in sALS roughly correlate with 615
our observations in the sALS/sFTLD-TDP spectrum 616
[45, 51] although the lack of information regarding 617
the cognitive status of patients in the c9ALS/sALS 618
comparative study does not permit further analogies 619
between the separate series. That study was per- 620
formed using RNA-sequencing methods [83], which 621
uses high-throughput sequencing to document all 622
transcripts in contrast to microarrays which quantify 623
a set of predetermined sequences. Therefore, RNA- 624
seq is presumably more robust than our microarrays 625
Un
co
rre
cte
d A
uth
or
 P
ro
of
P. Andre´s-Benito et al. / Frontal Cortex in FTLD Linked to C9ORF72 Expansion 17
approach, and may account for differences in the626
results obtained by these different strategies. How-627
ever, focusing on c9ALS and present observations628
in c9FTLD, altered RNA splicing and ubiquitin-629
proteasome system are identified in both studies.630
Comparisons with other studies performed in631
different types of FTLD-TDP show disparate632
results. One gene expression analysis in fFTLD633
linked to GRN mutations identified abnormal reg-634
ulated processes associated with lipid metabolism,635
MAPK signaling pathway, and transport [43],636
while lysosomal dysfunction was identified in637
another [44]. Another study recognized synapse-,638
cytoskeletal/filament-, microtubule/axon-, and639
proteasome-related pathways in FTLD-TDP when640
compared with controls, and cytoskeletal protein-,641
mitochondria/energy-, synapse-, microtubule/axon-,642
and ubiquitin-proteasome-associated deregulation643
when comparing FTLD-TDP with FTLD asso-644
ciated with motor neuron disease [42]. Common645
mechanisms occur within the FTLD-ALS spectrum646
[84]. However, weighted co-expression network647
proteomic analysis has recently revealed 15 modules648
of co-expressed proteins, eight of which differed649
significantly across the ALS-FTD disease spectrum650
[46]. Interestingly, a module enriched with astrocyte651
and microglia proteins was significantly increased652
in the frontal cortex in ALS cases carrying the653
C9orf72 mutation compared to sporadic ALS cases,654
suggesting that the genetic expansion is associated655
with inflammation in the brain [46]. Increased levels656
of proteins linked to inflammation are also identified657
in the frontal cortex in C9orf72 in our study. The658
present dual-omic approach, like the majority of659
molecular studies carried out in the postmortem660
human brain, is based on the relative abundance661
of particular mRNAs and proteins or ratios of two662
absolute concentrations (fold-change) representing663
concentrations relative to reference samples. More-664
over, the agonal state and postmortem delay may665
differentially interfere with transcription and protein666
synthesis/degradation. Therefore, when analyzing667
postmortem brain samples, a non-steady-state668
condition is always the real scenario. This statement669
is important when assessing transcripts and proteins670
separately, but it is especially crucial when analyzing671
RNA and protein correlations of particular genes672
in human postmortem brain [85–87]. Moreover,673
distinct cell populations are usually mingled, and674
rates and scales of RNA and corresponding encoded675
proteins may be cell type-dependent. These facts,676
together with particular characteristics of samples,677
and differences in the procedures and methods, may 678
account for the non-homogeneous results in different 679
laboratories. Although the original samples are the 680
same in the present series, and the identified altered 681
pathways are similar and complementary using a 682
combination of transcriptomics and proteomics, it 683
is worth stressing that different RNAs and proteins 684
are identified by these methods. Combined non- 685
targeted ‘-omics’ seems to be a valuable approach 686
to deciphering altered molecular pathways in FTLD 687
provided that observations are viewed cautiously 688
when assessing human postmortem brain samples. 689
ACKNOWLEDGMENTS 690
We wish to thank Valle de Hebron Institute of 691
Research (VHIR) Whole-transcriptome array plat- 692
form for their help in the arrays, and T. Yohannan 693
for editorial assistance. 694
This study was supported by grants from 695
CIBERNED and PI17/00809 Institute of Health Car- 696
los III, and co-funded by FEDER funds/European 697
Regional Development Fund (ERDF) – a way to 698
build Europe; ALS intra-CIBERNED project to IF; 699
IFI15/00035 fellowship to PA-B; “Retos todos unidos 700
contra la ELA” and “Proyecto DGeneracio´n conex- 701
iones con sentido” to MP; and grant from the 702
“Fundacio´n Tatiana Pe´rez de Guzma´n el Bueno, con- 703
vocatoria Neurociencias 2014” to EG. Additional 704
support came from grants from the Department 705
of Economic Development of the Government of 706
Navarra (Ref. PC025, PC081-82) to ES. The Pro- 707
teomics Unit of Navarrabiomed is a member of 708
Proteored, PRB3-ISCIII, and is supported by grant 709
PT17/0019, of the PE I + D + i 2013-2016 to JFI, 710
funded by ISCIII and ERDF. 711
Authors’ disclosures available online (https:// 712
www.j-alz.com/manuscript-disclosures/18-1123r2). 713
SUPPLEMENTARY MATERIAL 714
The supplementary material is available in the 715
electronic version of this article: http://dx.doi.org/ 716
10.3233/JAD-181123. 717
REFERENCES 718
[1] Hortobagyi T, Cairns NJ (2015) Amyotrophic lateral 719
sclerosis and frontotemporal lobar degeneration. In Neu- 720
ropathology of neurodegenerative diseases: A practical 721
guide, Kovacs GG, ed. Cambridge University Press, Cam- 722
bridge, pp. 209-248. 723
Un
co
rre
cte
d A
uth
or
 P
ro
of
18 P. Andre´s-Benito et al. / Frontal Cortex in FTLD Linked to C9ORF72 Expansion
[2] Lashley T, Roher JD, Mead S, Revesz T (2015) Review:724
An update on clinical, genetic and pathological aspects of725
frontotemporal lobar degenerations. Neuropathol Appl Neu-726
robiol 41, 858-881.727
[3] Mann DMA, Snowden JS (2017) Frontotemporal lobar728
degeneration: Pathogenesis, pathology and pathways to phe-729
notype. Brain Pathol 27, 723-736.730
[4] Van Mossevelde S, Engelborghs S, van der Zee J,731
Broeckhoven C (2018) Genotype-phenotype links in fron-732
totemporal lobar degeneration. Nature Rev Neurol 14,733
363-378.734
[5] Olszewska DA, Lonergan R, Fallon EM, Lynch T (2016)735
Genetics of frontotemporal dementia. Curr Neurol Neurosci736
Rep 16, 107.737
[6] Pottier C, Ravenscroft TA, Sa´nchez-Contreras M, Rade-738
makers R (2016) Genetics of FTLD: Overview and what739
else we can expect from genetic studies. J Neurochem 138,740
32-53.741
[7] Rainero I, Rubino E, Michelerio A, D’Agata F, Gentile S,742
Pinessi L (2017) Recent advances in the molecular genet-743
ics of frontotemporal lobar degeneration. Funct Neurol 32,744
7-16.745
[8] Neumann M, Mackenzie IRA (2019) Neuropathology of746
non-tau frontotemporal lobar degeneration. Neuropathol747
Appl Neurobiol 45, 19-40.748
[9] Neumann M, Sampathu DM, Kwong LK, Truax AC, Mic-749
senyi MC, Chou TT, Bruce J, Schuck T, Grossman M, Clark750
CM, McCluskey LF, Miller BL, Masliah E, Mackenzie IR,751
Feldman H, Feiden W, Kretzschmar HA, Trojanowski JQ,752
Lee VM (2006) Ubiquitinated TDP-43 in frontotemporal753
lobar degeneration and amyotrophic lateral sclerosis. Sci-754
ence 314, 130-133.755
[10] Geser F, Martinez-Lage M, Robinson J, Uryu K, Neu-756
mann M, Brandmeir NJ, Xie SX, Kwong LK, Elman L,757
McCluskey L, Clark CM, Malunda J, Miller BL, Zimmer-758
man EA, Qian J, Van Deerlin V, Grossman M, Lee VM,759
Trojanowski JQ (2009) Clinical and pathological contin-760
uum of multisystem TDP-43 proteinopathies. Arch Neurol761
66, 180-189.762
[11] DeJesu´s-Herna´ndez M, Mackenzie IR, Boeve BF, Boxer763
AL, Baker M, Rutherford NJ, Nicholson AM, Finch NA,764
Flynn H, Adamson J, Kouri N, Wojtas A, Sengdy P, Hsi-765
ung GY, Karydas A, Seeley WW, Josephs KA, Coppola G,766
Geschwind DH, Wszolek ZK, Feldman H, Knopman DS,767
Petersen RC, Miller BL, Dickson DW, Boylan KB, Graff-768
Radford NR, Rademakers R (2011) Expanded GGG GCC769
hexanucleotide repeat in non-coding region of C9ORF72770
causes chromosome 9p-linked FTD and ALS. Neuron 72,771
245-256.772
[12] Cruts M, Gijselinck I, Van Langenhove T, Van der Zee773
J, Van Broeckhoven C (2013) Current insights into the774
C9orf72 repeat expansion diseases of the FTLD/ALS spec-775
trum. Trends Neurosci 36, 450-499.776
[13] Renton AE, Chio` A, Traynor BJ (2014) State of play in777
amyotrophic lateral sclerosis genetics. Nat Neurosci 17,778
17-23.779
[14] Stewart H, Rutherford NJ, Briemberg H, Krieger C, Cash-780
man N, Fabros M, Baker M, Fok A, DeJesu´s-Herna´ndez781
M, Eisen A, Rademakers R, Mackenzie IR (2012) Clinical782
and pathological features of amyotrophic lateral sclerosis783
caused by mutation in the C9ORF72 gene on chromosome784
9p. Acta Neuropathol 123, 409-417.785
[15] Boeve BF, Boylan KB, Graff-Radford NR, DeJesus-786
Hernandez M, Knopman DS, Pedraza O, Vemuri P, Jones D,787
Lowe V, Murray ME, Dickson DW, Josephs KA, Rush BK,788
Machulda MM, Fields JA, Ferman TJ, Baker M, Rutherford 789
NJ, Adamson J, Wszolek ZK, Adeli A, Savica R, Boot B, 790
Kuntz KM, Gavrilova R, Reeves A, Whitwell J, Kantarci K, 791
Jack CR Jr, Parisi JE, Lucas JA, Petersen RC, Rademakers 792
R (2012) Characterization of frontotemporal dementia GCC 793
repeat expansion in C9ORF72. Brain 135, 765-783. 794
[16] Gendron TF, Bieniek KF, Zhang YJ, Jansen-West K, Ash 795
PE, Caulfield T, Daughrity L, Dunmore JH, Castanedes- 796
Casey M, Chew J, Cosio DM, van Blitterswijk M, Lee 797
WC, Rademakers R, Boylan KB, Dickson DW, Petrucelli 798
L (2013) Antisense transcripts of the expanded C9ORF72 799
hexanucleotide repeat form nuclear RNA foci and undergo 800
repeat-associated non-ATG translation in c9FTD/ALS. Acta 801
Neuropathol 126, 829-844. 802
[17] Lee YB, Chen HJ, Peres JN, Gomez-Deza J, Attig J, Stalekar 803
M, Troakes C, Nishimura AL, Scotter EL, Vance C, Adachi 804
Y, Sardone V, Miller JW, Smith BN, Gallo JM, Ule J, 805
Hirth F, Rogelj B, Houart C, Shaw CE (2013) Hexanu- 806
cleotide repeats in ALS/FTD form length-dependent RNA 807
foci, sequester RNA binding proteins, and are neurotoxic. 808
Cell Rep 5, 1178-1186. 809
[18] Donnelly CJ, Zhang PW, Pham JT, Haeusler AR, Mistry 810
NA, Vidensky S, Daley EL, Poth EM, Hoover B, Fines 811
DM, Maragakis N, Tienari PJ, Petrucelli L, Traynor BJ, 812
Wang J, Rigo F, Bennett CF, Blackshaw S, Sattler R, Roth- 813
stein JD (2013) RNA toxicity from the ALS/FTD C9ORF72 814
expansion is mitigated by antisense intervention. Neuron 80, 815
415-428. 816
[19] Sareen D, O’Rourke JG, Meera P, Muhammad AK, Grant 817
S, Simpkinson M, Bell S, Carmona S, Ornelas L, Sahabian 818
A, Ornelas L, Sahabian A, Gendron T, Petrucelli L, 819
Baughn M, Ravits J, Harms MB, Rigo F, Bennett CF, 820
Otis TS, Svendsen CN, Baloh RH (2013) Targeting RNA 821
foci in iPSC-derived motor neurons from ALS patients 822
with a C9ORF72 repeat expansion. Sci Transl Med 5, 823
208ra149. 824
[20] Mizielinska S, Lashley T, Norona FE, Clayton EL, Ridler 825
CE, Fratta P, Isaacs AM (2013) C9orf72 frontotemporal 826
lobar degeneration is characterised by frequent neuronal 827
sense and antisense RNA foci. Acta Neuropathol 126, 828
845-857. 829
[21] May S, Hornburg D, Schludi MH, Arzberger T, Rentzsch 830
K, Schwenk BM, Grasser FA, Mori K, Kremmer E, 831
Banzhaf-Strathmann, Mann M, Meissner F (2014) C9orf72 832
FTLD/ALS-associated Gly-Ala dipeptide repeat proteins 833
cause neuronal toxicity and Unc119 sequestration. Acta 834
Neuropathol 128, 485-503. 835
[22] Zhang YJ, Jansen-West K, Xu YF, Gendron TF, Bie- 836
niek KF, Lin WL, Sasaguri H, Caulfield T, Hubbard J, 837
Daughrity L, Chew J, Belzil VV, Prudencio M, Stankowski 838
JN, Castanedes-Casey M, Whitelaw E, Ash PE, DeTure 839
M, Rademakers R, Boylan KB, Dickson DW, Petru- 840
celli L (2014) Aggregation-prone c9FTD/ALS poly(GA) 841
RANtranslated proteins cause neurotoxicity by inducing ER 842
stress. Acta Neuropathol 128, 505-524. 843
[23] Wen X, Tan W, Westergard T, Krishnamurthy K, Markanda- 844
iah SS, Shi Y, Lin S, Shneider NA, Monaghan J, Pandey UB, 845
Pasinelli P, Ichida JK, Trotti D (2014) Antisense proline- 846
arginine RAN dipeptides linked to C9ORF72-ALS/FTD 847
form toxic nuclear aggregates that initiate in vitro and in 848
vivo neuronal death. Neuron 84, 1213-1225. 849
[24] Cooper-Knock J, Walsh MJ, Higginbottom A, Robin High- 850
ley J, Dickman MJ, Edbauer D, Ince PG, Wharton SB, 851
Wilson SA, Kirby J Wharton SB, Wilson SA, Kirby J, 852
Hautbergue GM, Shaw PJ (2014) Sequestration of multi- 853
Un
co
rre
cte
d A
uth
or
 P
ro
of
P. Andre´s-Benito et al. / Frontal Cortex in FTLD Linked to C9ORF72 Expansion 19
ple RNA recognition motif-containing proteins by C9orf72854
repeat expansions. Brain 137, 2040-2051.855
[25] Kwon I, Xiang S, Kato M, Wu L, Theodoropoulos P, Wang856
T, Kim J, Yun J, Xie Y, McKnight SL (2014) Poly-dipeptides857
encoded by the C9orf72 repeats bind nucleoli, impede RNA858
biogenesis, and kill cells. Science 345, 1139-1145.859
[26] Freibaum BD, Lu Y, Lopez-Gonzalez R, Kim NC, Almeida860
S, Lee KH, Badders N, Valentine M, Miller BL, Wong PC,861
Petrucelli L, Kim HJ, Gao FB, Taylor JP (2015) GGG GCC862
repeat expansion in C9orf72 compromises nucleocytoplas-863
mic transport. Nature 525, 129-133.864
[27] Tao Z, Wang H, Xia Q, Li K, Li K, Jiang X, Xu G, Wang G,865
Ying Z (2015) Nucleolar stress and impaired stress granule866
formation contribute to C9orf72 RAN translation-induced867
cytotoxicity. Hum Mol Genet 24, 2426-2441.868
[28] Jovicic A, Mertens J, Boeynaems S, Bogaert E, Chai N,869
Yamada SB, Paul JW 3rd, Sun S, Herdy JR, Bieri G, Kramer870
NJ, Gage FH, Van Den Bosch L, Robberecht W, Gitler AD871
(2015) Modifiers of C9orf72 dipeptide repeat toxicity con-872
nect nucleo-cytoplasmic transport defects to FTD/ALS. Nat873
Neurosci 18, 1226-1229.874
[29] Schludi MH, May S, Grasser FA, Rentzsch K, Kremmer E,875
Kupper C, Klopstock T, Arzberger T, German Consortium876
for Frontotemporal Lobar Degeneration, Bavarian Brain877
Banking (2015) Distribution of dipeptide repeat proteins in878
cellular models and C9orf72 mutation cases suggests link to879
transcriptional silencing. Acta Neuropathol 130, 537-555.880
[30] Porta S, Kwong LK, Trojanowski JQ, Lee VM (2015)881
Drosha inclusions are new components of dipeptide-repeat882
protein aggregates in FTLD-TDP and ALS C9orf72 expan-883
sion cases. J Neuropathol Exp Neurol 74, 380-387.884
[31] Todd TW, Petrucelli L (2016) Insights into the pathogenic885
mechanisms of chromosome 9 open reading frame 72886
(C9orf72) repeat expansions. J Neurochem 138, 145-162.887
[32] Cooper-Knock J, Higginbottom A, Stopford MJ, Highley888
JR, Ince PG, Wharton SB, Pickering-Brown S, Kirby J,889
Hautbergue GM, Shaw PJ (2015) Antisense RNA foci in890
the motor neurons of C9ORF72-ALS patients are associated891
with TDP-43 proteinopathy. Acta Neuropathol 130, 63-75.892
[33] Xiao S, MacNair L, McLean J, McGoldrick P, McKeever893
P, Soleimani S, Keith J, Zinman L, Rogaeva E, Robertson894
J (2016) C9orf72 isoforms in amyotrophic lateral sclero-895
sis and frontotemporal lobar degeneration. Brain Res 1647,896
43-49.897
[34] Zhang YJ, Gendron TF, Grima JC, Sasaguri H, Jansen-West898
K, Xu YF, Katzman RB, Gass J, Murray ME, Shinohara899
M, Lin WL, Garrett A, Stankowski JN, Daughrity L, Tong900
J, Perkerson EA, Yue M, Chew J, Castanedes-Casey M,901
Kurti A, Wang ZS, Liesinger AM, Baker JD, Jiang J,902
Lagier-Tourenne C, Edbauer D, Cleveland DW, Rademak-903
ers R, Boylan KB, Bu G, Link CD, Dickey CA, Rothstein904
JD, Dickson DW, Fryer JD, Petrucelli L (2016) C9ORF72905
poly(GA) aggregates sequester and impair HR23 and nucle-906
ocytoplasmic transport proteins. Nat Neurosci 19, 668-677.907
[35] Gao FB, Almeida S, Lo´pez-Gonza´lez R (2017) Dys-908
regulated molecular pathways in amyotrophic lateral909
sclerosis–frontotemporal dementia spectrum disorder.910
EMBO J 36, 2931-2950.911
[36] DeJesu´s-Herna´ndez M, Finch NA, Wang X, Gendron TF,912
Bieniek KF, Heckman MG, Vasilevich A, Murray ME,913
Rousseau L, Weesner R, Lucido A, Parsons M, Chew J,914
Josephs KA, Parisi JE, Knopman DS, Petersen RC, Boeve915
BF, Graff-Radford NR, de Boer J, Asmann YW, Petrucelli916
L, Boylan KB, Dickson DW, van Blitterswijk M, Rademak-917
ers R (2017) In-depth clinico-pathological examination of918
RNA foci in a large cohort of C9ORF72 expansion carriers. 919
Acta Neuropathol 134, 255-269. 920
[37] Budini M, Buratti E, Morselli E, Criollo A (2017) 921
Autophagy and its impact on neurodegenerative diseases: 922
New roles for TDP-43 and C9orf72. Front Mol Neurosci 923
10, 170. 924
[38] Ji YJ, Ugolino J, Brady NR, Hamacher-Brady A, Wang J 925
(2017) Systemic deregulation of autophagy upon loss of 926
ALS- and FTD-linked C9orf72. Autophagy 13, 1254-1255. 927
[39] Vatsavayai SC, Nana AL, Yokoyama JS, Seeley WW (2019) 928
C9orf72-FTD/ALS pathogenesis: Evidence from human 929
neuropathological studies. Acta Neuropathol 137, 1-26. 930
[40] Zhang Y, Burberry A, Wang JY, Sandoe J, Ghosh S, Udeshi 931
ND, Svinkina T, Mordes DA, Mok J, Charlton M, Li QZ, 932
Carr SA, Eggan K (2018) The C9orf72-interacting protein 933
Smcr8 is a negative regulator of autoimmunity and lysoso- 934
mal exocytosis. Genes Dev 32, 929-943. 935
[41] Herrmann D, Parlato R (2018) C9orf72-associated neurode- 936
generation in ALS-FTD: Breaking new ground in ribosomal 937
RNA and nucleolar dysfunction. Cell Tissue Res 373, 938
351-360. 939
[42] Mishra M, Paunesku T, Woloschak GE, Siddique T, Zhu 940
LJ, Lin S, Greco K, Bigio EH (2007) Gene expression 941
analysis of frontotemporal lobar degeneration of the motor 942
neuron disease type with ubiquitinated inclusions. Acta Neu- 943
ropathol 114, 81-94 944
[43] Chen-Plotkin AS, Geser F, Plotkin JB, Clark CM, Kwong 945
LK, Yuan W, Grossman M, Van Deerlin VM, Trojanowski 946
JQ, Lee VM (2008) Variations in the progranulin gene affect 947
global gene expression in frontotemporal lobar degenera- 948
tion. Hum Mol Genet 17, 1349-1362. 949
[44] Evers BM, Rodrı´guez-Navas C, Tesla RJ, Prange-Kiel J, 950
Wasser CR, Yoo KS, McDonald J, Cenik B, Ravenscroft 951
TA, Plattner F, Rademakers R, Yu G, White CL 3rd, Herz 952
J (2017) Lipidomic and transcriptomic basis of lysoso- 953
mal dysfunction in progranulin deficiency. Cell Rep 20, 954
2565-2574. 955
[45] Andre´s-Benito P, Gelpi E, Povedano M, Santpere G, Ferrer I 956
(2018) Gene expression profile in frontal cortex in sporadic 957
frontotemporal lobar degeneration-TDP. J Neuropathol Exp 958
Neurol 77, 608-627. 959
[46] Umoh ME, Dammer EB, Dai J, Duong DM, Lah JJ, Levey 960
AI, Gearing M, Glass JD, Seyfried NT (2018) A proteomic 961
network approach across the ALS-FTD disease spectrum 962
resolves clinical phenotypes and genetic vulnerability in 963
human brain. EMBO Mol Med 10, 48-62. 964
[47] Mackenzie IR, Neumann M, Baborie A, Sampathu DM, 965
Du Plessis D, Jaros E, Perry RH, Trojanowski JQ, Mann 966
DM, Lee VM (2011) A harmonized classification system 967
for FTLD-TDP pathology. Acta Neuropathol 122, 111-113. 968
[48] Brettschneider J, Del Tredici K, Irwin DJ, Grossman M, 969
Robinson JL, Toledo JB, Fang L, Van Deerlin VM, Ludolph 970
AC, Lee VM, Braak H, Trojanowski JQ (2014) Sequen- 971
tial distribution of pTDP-43 pathology in behavioral variant 972
frontotemporal dementia (bvFTD). Acta Neuropathol 127, 973
423-439. 974
[49] Durrenberger PF, Fernando S, Kashefi SN, Ferrer I, Hauw 975
JJ, Seilhean D, Smith C, Walker R, Al-Sarraj S, Troakes C, 976
Palkovits M, Kasztner M, Huitinga I, Arzberger T, Dexter 977
DT, Kretzschmar H, Reynolds R (2010) Effects of ante- 978
mortem and postmortem variables on human brain mRNA 979
quality: A BrainNet Europe study. J Neuropathol Exp Neu- 980
rol 69, 70-81. 981
[50] Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling 982
M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, Hornik K, 983
Un
co
rre
cte
d A
uth
or
 P
ro
of
20 P. Andre´s-Benito et al. / Frontal Cortex in FTLD Linked to C9ORF72 Expansion
Hothorn T, Huber W, Iacus S, Irizarry R, Leisch F, Li C,984
Maechler M, Rossini AJ, Sawitzki G, Smith C, Smyth G,985
Tierney L, Yang JY, Zhang J (2004). Bioconductor: Open986
software development for computational biology and bioin-987
formatics. Genome Biol 5, R80.988
[51] Andre´s-Benito P, Moreno J, Aso E, Povedano M, Ferrer I989
(2017) Amyotrophic lateral sclerosis, gene deregulation in990
the anterior horn of the spinal cord and frontal cortex area991
8: Implications in frontotemporal lobar degeneration. Aging992
9, 823-851.993
[52] Durrenberger PF, Fernando FS, Magliozzi R, Kashefi SN,994
Bonnert TP, Ferrer I, Seilhean D, Nait-Oumesmar B,995
Schmitt A, Gebicke-Haerter PJ, Falkai P, Gru¨nblatt E,996
Palkovits M, Parchi P, Capellari S, Arzberger T, Kret-997
zschmar H, Roncaroli F, Dexter DT, Reynolds R (2012)998
Selection of novel reference genes for use in the human999
central nervous system: A BrainNet Europe Study. Acta1000
Neuropathol 124, 893-903.1001
[53] Tang WH, Shilov IV, Seymour SL (2008) Nonlinear fit-1002
ting method for determining local false discovery rates from1003
decoy database searches. J Proteome Res 7, 3661.1004
[54] Tyanova S, Temu T, Sinitcyn P, Carlson A, Hein MY,1005
Geiger T, Mann M, Cox J (2016) The Perseus computa-1006
tional platform for comprehensive analysis of (prote)omics1007
data. Nature Methods 13, 731-740.1008
[55] Belzil VV, Bauer PO, Prudencio M, Gendron TF, Stetler CT,1009
Yan IK, Pregent L,Daughrity L, Baker MC, Rademakers1010
R, Boylan K, Patel TC, Dickson DW, Petrucelli L (2013)1011
Reduced C9orf72 gene expression in c9FTD/ALS is caused1012
by histone trimethylation, an epigenetic event detectable in1013
blood. Acta Neuropathol 126, 895-905.1014
[56] Ciura S, Lattante S, Le Ber I, Latouche M, Tostivint H, Brice1015
A, Kabashi E (2013) Loss of function of C9orf72 causes1016
motor deficits in a zebrafish model of amyotrophic lateral1017
sclerosis. Ann Neurol 74, 180-187.1018
[57] Xi Z, Zinman L, Moreno D, Schymick J, Liang Y, Sato C,1019
Zheng Y, Ghani M, Dib S, Keith J, Robertson J, Rogaeva E1020
(2013) Hypermethylation of the CpG island near the G4C21021
repeat in ALS with a C9orf72 expansion. Am J Hum Genet1022
92, 981-989.1023
[58] Waite AJ, Baumer D, East S, Neal J, Morris HR, Ansorge O,1024
Blake DJ (2014) Reduced C9orf72 protein levels in frontal1025
cortex of amyotrophic lateral sclerosis and frontotempo-1026
ral degeneration brain with the C9ORF72 hexanucleotide1027
repeat expansion. Neurobiol Aging 35, 1779.e5-1779.e13.1028
[59] Jung J, Behrends C (2017) Multifaceted role of SMCR8 as1029
autophagy regulator. Small GTPases 1, 1-9.1030
[60] Zhang YJ, Gendron TF, Ebbert MTW, O’Raw AD, Yue1031
M, Jansen-West K, Zhang X, Prudencio M, Chew J,1032
Cook CN, Daughrity LM, Tong J, Song Y, Pickles SR,1033
Castanedes-Casey M, Kurti A, Rademakers R2, Oskarsson1034
B, Dickson DW, Hu W, Gitler AD, Fryer JD, Petrucelli1035
L (2018) Poly(GR) impairs protein translation and stress1036
granule dynamics in C9orf72-associated frontotemporal1037
dementia and amyotrophic lateral sclerosis. Nat Med 24,1038
1136-1142.1039
[61] Frick P, Sellier C, Mackenzie IRA, Cheng CY, Tahraoui-1040
Bories J, Martinat C, Pasterkamp RJ, Prudlo J, Edbauer1041
D, Oulad-Abdelghani M, Feederle R, Charlet-Berguerand1042
N, Neumann M (2018) Novel antibodies reveal presynaptic1043
localization of C9orf72 protein and reduced protein levels1044
in C9orf72 mutation carriers. Acta Neuropathol Commun1045
6, 72.1046
[62] Kaus A, Sareen D (2015) ALS Patient stem cells for1047
unveiling disease signatures of motoneuron susceptibility:1048
Perspectives on the deadly mitochondria, ER stress and cal- 1049
cium triad. Front Cell Neurosci 9, 448. 1050
[63] Dafinca R, Scaber J, Ababneh N, Lalic T, Weir G, Chris- 1051
tian H, Vowles J, Douglas AG, Fletcher-Jones A, Browne 1052
C, Nakanishi M, Turner MR, Wade-Martins R, Cowley 1053
SA, Talbot K (2016) 9orf72 hexanucleotide expansions 1054
are associated with altered endoplasmic reticulum cal- 1055
cium homeostasis and stress granule formation in induced 1056
pluripotent stem cell-derived neurons from patients with 1057
amyotrophic lateral sclerosis and frontotemporal dementia. 1058
Stem Cells 34, 2063-2078. 1059
[64] Palluzzi F, Ferrari R, Graziano F, Novelli V, Rossi G, Gal- 1060
imberti D, Rainero I, Benussi L, Nacmias B, Bruni AC, Cusi 1061
D, Salvi E, Borroni B, Grassi M (2017) A novel network 1062
analysis approach reveals DNA damage, oxidative stress 1063
and calcium/cAMP homeostasis-associated biomarkers in 1064
frontotemporal dementia. PLoS One 12, e0185797. 1065
[65] Lau DHW, Hartopp N, Welsh NJ, Mueller S, Glennon EB, 1066
Mo´rotz GM, Annibali A, Gomez-Suaga P, Stoica R, Paillus- 1067
son S, Miller CCJ (2018) Disruption of ER-mitochondria 1068
signalling in fronto-temporal dementia and related amy- 1069
otrophic lateral sclerosis. Cell Death Dis 9, 327. 1070
[66] Evans CS, Holzbaur ELF (2019) Autophagy and mitophagy 1071
in ALS. Neurobiol Dis 122, 35-40. 1072
[67] Ayala V, Granado-Serrano AB, Cacabelos D, Naudı´ A, 1073
Ilieva EV, Boada J, Caraballo-Miralles V, Llado´ J, Ferrer 1074
I, Pamplona R, Portero-Otin M (2011) Cell stress induces 1075
TDP-43 pathological changes associated with ERK1/2 dys- 1076
function: Implications in ALS. Acta Neuropathol 122, 1077
259-270. 1078
[68] Cacabelos D, Ayala V, Granado-Serrano AB, Jove´ M, Tor- 1079
res P, Boada J, Cabre´ R, Ramı´rez-Nu´n˜ez O, Gonzalo H, 1080
Soler-Cantero A, Serrano JC, Bellmunt MJ, Romero MP, 1081
Motilva MJ, Nonaka T, Hasegawa M, Ferrer I, Pamplona 1082
R, Portero-Otı´n M (2016) Interplay between TDP-43 and 1083
docosahexaenoic acid-related processes in amyotrophic lat- 1084
eral sclerosis. Neurobiol Dis 88, 148-160. 1085
[69] Ilieva EV, Ayala V, Jove´ M, Dalfo´ E, Cacabelos D, Povedano 1086
M, Bellmunt MJ, Ferrer I, Pamplona R, Portero-Otı´n M 1087
(2007) Oxidative and endoplasmic reticulum stress inter- 1088
play in sporadic amyotrophic lateral sclerosis. Brain 130, 1089
3111-3123. 1090
[70] Martı´nez A, Carmona M, Portero-Otin M, Naudı´ A, Pam- 1091
plona R, Ferrer I (2008) Type-dependent oxidative damage 1092
in frontotemporal lobar degeneration: Cortical astrocytes 1093
are targets of oxidative damage. J Neuropathol Exp Neurol 1094
67, 1122-1136. 1095
[71] Ambros V (2004) The functions of animal microRNAs. 1096
Nature 431, 350-355. 1097
[72] Bartel DP (2004) MicroRNAs: Genomics, biogenesis, 1098
mechanism, and function. Cell 116, 281-297. 1099
[73] Enwerem II, Wu G, Yu YT, Hebert MD (2015) Cajal body 1100
proteins differentially affect the processing of box C/D 1101
scaRNPs. PLoS One 10, e0122348. 1102
[74] Ransohoff JD, Wei Y, Khavari PA (2018) The functions and 1103
unique features of long intergenic non-coding RNA. Nat 1104
Rev Mol Cell Biol 19, 143-157. 1105
[75] Chow JC, Yen Z, Ziesche SM, Brown CJ (2005) Silencing 1106
of the mammalian X chromosome. Annu Rev Genom Hum 1107
Genet 6, 69-92. 1108
[76] Ferrer I (2018) Oligodendrogliopathy in neurodegenerative 1109
diseases with abnormal protein aggregates: The forgotten 1110
partner. Progr Neurobiol 169, 24-54. 1111
[77] Neumann M, Kwong LK, Truax AC, Vanmassenhove B, 1112
Kretzschmar HA, Van Deerlin VM, Clark CM, Grossman 1113
Un
co
rre
cte
d A
uth
or
 P
ro
of
P. Andre´s-Benito et al. / Frontal Cortex in FTLD Linked to C9ORF72 Expansion 21
M, Miller BL, Trojanowski JQ, Lee VM (2007) TDP-43-1114
positive white matter pathology in frontotemporal lobar1115
degeneration with ubiquitin-positive inclusions. J Neu-1116
ropathol Exp Neurol 66, 177-183.1117
[78] Fatima M, Tan R, Halliday GM, Kril JJ (2015) Spread of1118
pathology in amyotrophic lateral sclerosis: Assessment of1119
phosphorylated TDP-43 along axonal pathways. Acta Neu-1120
ropathol Commun 3, 47.1121
[79] Bigio EH (2011) C9ORF72, the new gene on the block,1122
causes C9FTD/ALS: New insights provided by neu-1123
ropathology. Acta Neuropathol 122, 653-655.1124
[80] Bigio EH (2012) Motor neuron disease: The C9orf72 hex-1125
anucleotide repeat expansion in FTD and ALS. Nat Rev1126
Neurol 8, 249-250.1127
[81] Ferrer I (2017) Diversity of astroglial responses across1128
human neurodegenerative disorders and brain aging. Brain1129
Pathol 27, 645-674.1130
[82] Kovacs GG, Lee VM, Trojanowski JQ (2017) Protein1131
astrogliopathies in human neurodegenerative diseases and1132
aging. Brain Pathol 27, 675-690.1133
[83] Prudencio M, Belzil VV, Batra R, Ross CA, Gendron TF,1134
Pregent LJ, Murray ME, Overstreet KK, Piazza-Johnston1135
AE, Desaro P, Bieniek KF, DeTure M, Lee WC, Biendarra1136
SM, Davis MD, Baker MC, Perkerson RB, van Blitter-1137
swijk M, Stetler CT, Rademakers R, Link CD, Dickson DW,
Boylan KB, Li H, Petrucelli L (2015) Distinct brain tran- 1138
scriptome profiles in C9orf72-associated and sporadic ALS. 1139
Nat Neurosci 8, 251175-251182. 1140
[84] Conlon EG, Fagegaltier D, Agius P, Davis-Porada J, Gre- 1141
gory J, Hubbard I, Kang K, Kim D; New York Genome Cen- 1142
ter ALS Consortium, Phatnani H, Kwan J, Sareen D, Broach 1143
JR, Simmons Z, Arcila-Londono X, Lee EB, Van Deerlin 1144
VM, Shneider NA, Fraenkel E, Ostrow LW, Baas F, Zaitlen 1145
N, Berry JD, Malaspina A, Fratta P, Cox GA, Thompson 1146
LM, Finkbeiner S, Dardiotis E, Miller TM, Chandran S, Pal 1147
S, Hornstein E, MacGowan DJ, Heiman-Patterson T, Ham- 1148
mell MG, Patsopoulos NA, Dubnau J, Nath A, Phatnani 1149
H, Shneider NA, Manley JL (2018) Unexpected similari- 1150
ties between C9ORF72 and sporadic forms of ALS/FTD 1151
suggest a common disease mechanism. Elife 13, 7. 1152
[85] Vogel C, Marcotte EM (2012) Insights into the regulation 1153
of protein abundance from proteomic and transcriptomic 1154
analyses. Nat Rev Genet 13, 227-232. 1155
[86] Marguerat S, Schmidt A, Codlin S, Chen W, Aebersold R, 1156
Ba¨hler J (2012) Quantitative analysis of fission yeast tran- 1157
scriptomes and proteomes in proliferating and quiescent 1158
cells. Cell 151, 671-683. 1159
[87] Liu Y, Beyer A, Aebersold R (2016) On the dependency 1160
of cellular protein levels on mRNA abundance. Cell 165, 1161
535-550. 1162
